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In a previous study, we have shown that shortening of telomeres by
telomerase inhibition sensitized cancer cells to cisplatinum, slower
their migration, increased DNA damage and impaired DNA repair [1].
In the following study, we present a network model combining
microRNA and proteomic proﬁling attempting to decipher the
molecular mechanism underlying the effect of shortened telomeres
on the obtained phenotype of cancer cells [2]. The microRNA and
proteomic data were used for a network model construction, which
provided us with several nodal candidates that may potentially
mediate the shortened-telomeres dependent features. These protein
expressions were experimentally validated, supporting their poten-
tial central role in this system [2]. In this article, we delineate the full
proteomic data and a microarray analyses performed on cells with
shortened telomeres compared to their cognate parental intact
telomere cells. The data is attached as excel ﬁles. In principle,
clarifying the mechanism behind telomere shortened phenotype may
facilitate novel therapeutics development and may also obviate the
time consuming process of telomere shortening achieved by
telomerase inhibition.
& 2014 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ier Inc. This is an open access article under the CC BY license
/j.ygeno.2014.10.013
@gmail.com (O. Uziel).
O. Uziel, M. Lahav / Data in Brief 2 (2015) 48–51 49Speciﬁcations TableSubject area BiologyMore speciﬁc
subject areaThe biology of telomeres and telomerase in cancer and agingType of data Table
How data was
acquiredProteomic data was obtained by Quantitative mass spectroscopy (LTQ Orbitrap XL™ Hybrid Ion Trap-
OrbitrapMass Spectrometer, Thermoﬁsher).
Microarray data were obtained by DNA microarrays hybridization (Affymetrix GeneChips Human
Gene 1.0 ST arrays).Data format Raw
Experimental factors Prior to the proteomic analysis, control cells were grown in the presence of SILAC (Stable Isotope
Labeled Amino Acids) [3] and the experimental cells (in which telomerase was inhibited for 16
months exhibiting about 50% shortening) were grown in a standard growth media. For the
microarray analysis, the control and experimental cells were grown in a standard growth media.
Prior to the proteomic and microarray analyses telomerase inhibitor was withdrawn from the
experimental media group to normalize for active telomerase in both cell groups (see Materials and
Methods).Experimental
featuresFor the proteomic analysis cell cultures were grown for ﬁve population doublings as described above,
lysed and proteins were extracted and separated on a 10% polyacrylamide gel. The mixed protein
lane was divided into 10 pieces and subjected to quantitative mass spectrometry as described in [4].
For the microarray analysis cells were grown as described above, RNA was extracted by the RNeasy
mini kit (Qiagen, Hamburg, Germany) and measured by the Nanodrop (Thermo, Waltham, MA, USA),
visualized on an agarose gel, aliquoted and hybridized to DNA microarrays as described in the
Affymetrix website [5].Data source location Both analyses were conducted in Israel. The proteomic analysis was performed in The Smoler Protein
Research Center, The Technion, Haifa. The microarrays analysis was done at The Genome Center in
the Bioinformatic Unit, The George S. Wise Faculty of Life Sciences and the Sackler School of
Medicine in Tel Aviv University, Ramat Aviv.Data accessibility The data is with this article.Value of the data The issue of inhibiting telomerase as an anticancer target has been accelerated in the past decade.
Many telomerase compound have been developed, some of them are already in clinical trials [6].
The inhibition of telomerase activity shortens telomeres and subsequently damage cancer cells.
However, the mechanisms by which shortening of telomeres perturbs cancer cells are not fully
elucidated yet. The data presented here including the study described in [2] is an initial step for
understanding the mechanisms underlying cancer cells perturbation following telomeres
shortening. Here we present a full proteomic data together with microarray analysis of cells with shortened
telomeres versus the parental cells with intact telomeres. This data may be also valuable to
researchers who conduct similar analyses for evaluation and comparison.1. Data, experimental design, materials and methods
1.1. The experimental system
SK-N-MC (neuro-epithelial neuroblastoma/Ewing sarcoma) cells were exposed twice a week to
telomerase inhibitor, GRN163 (5 μM) for about 20 months (kindly donated by Dr. S. Gryaznov, Geron
Corp. Menlo Park, CA, USA). The telomerase inhibitor was thenwithdrawn from the growth media and
the cells were further grown for three additional population doublings to allow for elongation of the
shortest telomeres and complete reconstitution of telomerase activity. The control intact cells were
maintained in the culture medium without inhibitor. Telomere length was determined until
shortening of more than 50% of the original length. Another set of control cells were created by
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Fig. 1. A ﬂow chart of the study. See text for more detailed description of the experimental procedures.
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original size. See Fig. 1, the study ﬂow chart.
1.2. The proteomic analysis
Cells were grown in the presence of SILAC-containing medium according to the protocol described
by Mathias Mann, 2007 [3]. Basically, the control intact cells were grown in the presence isotope
labeled L-arginine and L-lysine amino acids and the cells with shortened telomeres were maintained
in a standard RPMI medium, containing “light” arginine and lysine. Both cell cultures were grown for
ﬁve population doublings, lysed and proteins were extracted and separated on a 10% polyacrylamide
gel. The mixed protein lane was divided into 10 pieces and subjected to quantitative mass
spectrometry as described in [4]. The chosen cutoff for over or underexpression of proteins was
twofold, after correcting the data to a 1:1 ratio. The proteomic data are summarized in Supplementary
Table 1 A, B.
1.3. The microarray analysis
RNAwas extracted from the above cells with the RNeasy mini kit (Qiagen, Hamburg, Germany) and
measured by the Nanodrop (Thermo, Waltham, MA, USA), visualized on an agarose gel, aliquoted and
hybridized to DNA microarrays (Affymetrix GeneChips Human Gene 1.0 ST arrays) as described in [5].
We used a total of eight chips in triplicates. Microarray analysis was performed on CEL ﬁles using
Parteks Genomics Suite TM, version 6.5 Copyright © 2010 [7]. Data were normalized and summarized
with the robust multi-average method [8] followed by ANOVA. Gene expression data were sorted
using cutoffs of po0.05 under FDR (false discovery rate) adjustment criteria of po0.0002 for NDF and
of po0.0005 for DF [9] and fold-difference cutoff of 1.5. The microarray data are summarized in
Supplementary Tables 2 A (all genes) and 2 B (fold change – short telomeres versus intact telomeres).Appendix A. Supporting information
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2014.12.003.References
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